Intellectual Property - February 10, 2015
Novo to Seek IPO for NNIT
Novo Nordisk A/S is seeking an Initial Public Offering (IPO) of NNIT A/S on NASDAQ OMX Copenhagen A/S (Nasdaq Copenhagen). NNIT is a wholly-owned subsidiary of Novo Nordisk A/S and one of Denmark’s leading IT service providers and consultancies. The company has been considering spinning off NNIT since last January, when it named a new […]
Intellectual Property - February 5, 2015
FDA, Veloxis Dispute Continues
The U.S. Food and Drug Administration (FDA) has informed Veloxis Pharmaceuticals A/S that the FDA still maintains that the exclusivity for Astagraf XL should require delays in the formal approval of Envarsus® XR. The FDA has stated that it would be prepared to approve Envarsus XR for use only in patients transitioned from an immediate […]
Intellectual Property - December 15, 2014
Japan Grants Patent to Nordic Nanovector
The Japan Patent Office (JPO) has issued patent no. 5646652 entitled “NOVEL RADIOIMMUNOCONJUGATES AND USES THEREOF” to Nordic Nanovector. The issued claims cover Nordic Nanovector’s proprietary radioimmunotherapy (RIT) technology, including the company`s lead product candidate Betalutin™, a new targeted agent for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL).
Financing - October 16, 2014
Forward Pharma prices IPO of ADSs
Danish Forward Pharma A/S has announced the pricing of its initial public offering of 10,500,000 American Depositary Shares, ADSs. The ADSs represent the biopharmaceutical’s ordinary shares at a price to the public of USD 21.00 per ADS. The share were expected to begin trading on October 15 on the NASDAQ Global Select Market under the ticker […]
Drug development - September 8, 2014
BerGenBio granted platform patent
The Norwegian oncology biopharmaceutical company has announced that the United States Patent and Trademark Office (USPTO) has issued United States Patent 8,735,064 covering a method for creating and identifying functional interference RNA (RNAi) molecules. RNAis are recombinant nucleic acid molecules that have the ability to specifically down-regulate an expressed target gene in vivo. This patent protects BerGenBio’s CellSelect(TM) platform technology […]
Intellectual Property - September 3, 2014
AstraZeneca lost patent controversy
Teva has announced that the UK High Court gives positive judgment in the company’s patent case against AstraZeneca. The case regards the validity of EP 1,085,877 covering the SMART (Single inhaler Maintenance And Reliever Therapy) indication for AstraZeneca’s fixed dose formoterol/budesonide combination product, Symbicort. Teva said that the court agreed with Teva that AstraZeneca’s patent covering […]
